Alfimeprase: a novel recombinant direct-acting fibrinolytic.
Expert Opin Biol Ther
; 6(12): 1361-9, 2006 Dec.
Article
em En
| MEDLINE
| ID: mdl-17223743
ABSTRACT
Alfimeprase is a recombinant, direct-acting fibrinolytic zinc metalloprotease. Alfimeprase has direct proteolytic activity primarily against the fibrin(ogen) Aalpha chain. Alfimeprase is covalently bound and neutralised by serum alpha(2)-macroglobulin, a prevalent mammalian protease inhibitor. Preclinical pharmacology studies have shown that fibrinolysis with alfimeprase is up to sixfold more rapid than with select plasminogen activators, such as tissue-type plasminogen activator and urokinase. Alfimeprase directly delivered to a site of thrombosis has the potential to be a fast and effective fibrinolytic, which does not generate the systemic lytic state seen with plasminogen activators that is associated with major bleeding, including intracerebral haemorrhage. Phase I and II studies in individuals with arterial or venous thrombotic events indicate that alfimeprase is active and generally well tolerated.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Proteínas Recombinantes
/
Metaloendopeptidases
/
Drogas em Investigação
/
Fibrinolíticos
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Expert Opin Biol Ther
Assunto da revista:
BIOLOGIA
/
TERAPEUTICA
Ano de publicação:
2006
Tipo de documento:
Article
País de afiliação:
Estados Unidos